However, cholinesterase inhibitors and NMDA receptor antagonists are primarily classified as symptomatic treatments, as they mainly temporarily relieve symptoms or control neuropsychiatric symptoms, distinguishing them from disease-modifying treatments (DMTs) that affect the underlying biological AD pathology. Here, BCHE is linked to Alzheimer disease.